Stock Scorer

Accustem Sciences Inc. (ACUT)

Accustem Sciences Inc. reported revenue of 98.4K USD for the quarter ending 30 June 2026.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 98.4K —
Operating Income Q2 '26 · ending 30 June 2026 -252.6K —
Net Income Q2 '26 · ending 30 June 2026 -252.6K —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -248.8K -1253.8%
Free Cash Flow Q4 '22 · ending 31 December 2022 -622.3K —
Shares Outstanding Q2 '26 · ending 30 June 2026 16.1M +26.3%
EPS Q2 '26 · ending 30 June 2026 -0.11 —

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3098.4K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-252.6K
Q1 '262026-03-31-485.9K
Q4 '252025-12-31-514.4K
Q3 '252025-09-30-399.9K
Q2 '252025-06-30-401.4K
Q1 '252025-03-31-440.4K
Q4 '242024-12-31-372.1K
Q3 '242024-09-30-328.2K
Q2 '242024-06-30-278.2K
Q1 '242024-03-31-526.6K
Q4 '232023-12-31-246K
Q3 '232023-09-30-598.5K
Q2 '232023-06-30-372.8K
Q1 '232023-03-31-833.3K
Q4 '222022-12-31-978.5K
Q3 '222022-09-30-899.1K
Q2 '222022-06-30-1.1M
Q1 '222022-03-31-790.5K
Q4 '212021-12-31-543.5K
Q3 '212021-09-30-62.7K

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-252.6K
Q1 '262026-03-31-485.9K
Q4 '252025-12-31-514.4K
Q3 '252025-09-30-399.9K
Q2 '252025-06-30-401.4K
Q1 '252025-03-31-440.4K
Q4 '242024-12-31-372.1K
Q3 '242024-09-30-328.2K
Q2 '242024-06-30-278.2K
Q1 '242024-03-31-526.6K
Q4 '232023-12-31-246K
Q3 '232023-09-30-598.5K
Q2 '232023-06-30-372.8K
Q1 '232023-03-31-833.3K
Q4 '222022-12-31-978.5K
Q3 '222022-09-30-899.1K
Q2 '222022-06-30-1.1M
Q1 '222022-03-31-790.5K
Q4 '212021-12-31-543.5K
Q3 '212021-09-30-62.7K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-248.8K
Q1 '262026-03-31-374.2K
Q4 '252025-12-3122.4K
Q3 '252025-09-30-604.1K
Q2 '252025-06-3021.6K
Q1 '252025-03-31-290.2K
Q4 '242024-12-31414
Q3 '242024-09-30-217.9K
Q2 '242024-06-30-209.2K
Q1 '242024-03-31-237.4K
Q4 '232023-12-31-295K
Q3 '232023-09-30-351.6K
Q2 '232023-06-30-522.9K
Q1 '232023-03-31-446.1K
Q4 '222022-12-31-622.3K
Q3 '222022-09-30-555.3K
Q2 '222022-06-30-1M
Q1 '222022-03-31372K

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '222022-12-31-622.3K
Q3 '222022-09-30-555.3K
Q2 '222022-06-30-1M
Q1 '222022-03-31363.8K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3016.1M
Q1 '262026-03-3116.1M
Q3 '252025-09-3016.1M
Q2 '252025-06-3016.1M
Q1 '252025-03-3112.7M
Q3 '242024-09-3011.3M
Q2 '242024-06-3011.3M
Q1 '242024-03-3111.3M
Q3 '232023-09-3011.3M
Q2 '232023-06-3011.3M
Q1 '232023-03-3111.3M
Q3 '222022-09-3011.3M
Q2 '222022-06-3011.3M
Q1 '222022-03-3110M
Q3 '212021-09-3010M
Q2 '212021-06-3010M
Q1 '212021-03-3110M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.11
Q1 '262026-03-31-0.11
Q4 '252025-12-31-0.11
Q3 '252025-09-30-0.10
Q2 '252025-06-30-0.11
Q1 '252025-03-31-0.11
Q4 '242024-12-31-0.13
Q3 '242024-09-30-0.12
Q2 '242024-06-30-0.14
Q1 '242024-03-31-0.15
Q4 '232023-12-31-0.17
Q3 '232023-09-30-0.24
Q2 '232023-06-30-0.27
Q1 '232023-03-31-0.34
Q4 '222022-12-31-0.35
Q3 '222022-09-30-0.32
Q2 '222022-06-30-0.25
Q1 '222022-03-31-0.16
Q4 '212021-12-31-0.08